研究表明：中药为应对某类“超级细菌”提供新选择

Core Viewpoint - The study conducted by the team at Guang'anmen Hospital indicates that the traditional Chinese medicine formula Xinjia Dayuan San shows significant advantages in treating multidrug-resistant Gram-negative bacterial pneumonia, providing a new therapeutic option for patients facing high mortality rates due to limited treatment choices [1][2]. Group 1: Research Findings - The clinical trial, which took place from June 2022 to March 2025, involved 224 hospitalized adult patients diagnosed with multidrug-resistant Gram-negative bacterial pneumonia [1]. - The study demonstrated a statistically significant improvement in microbiological clearance rates by day 7 for patients treated with Xinjia Dayuan San compared to standard treatments [1]. - The clinical benefits of Xinjia Dayuan San were associated with a notable reduction in key pro-inflammatory cytokines [1]. Group 2: Safety and Efficacy - The overall safety assessment of the study indicated that the safety profile of the Xinjia Dayuan San group was comparable to that of the standard antibiotic control group [2]. - Experts believe that Xinjia Dayuan San exhibits immunomodulatory and anti-inflammatory effects, supporting its potential as an adjunctive treatment for multidrug-resistant bacteria [2]. - The research team plans to further explore and develop this finding to enhance the role of traditional Chinese medicine in addressing complex health challenges [2].